Calpain 2 and Lenvatinib Resistance in Liver Cancer
Author Information
Author(s): Ma Xiaolu, Zhou Kaixia, Yan Tianqing, Hu Ling, Xie Suhong, Zheng Hui, Tong Ying, Zhang Heng, Wang Yanchun, Gong Zhiyun, Chen Cuncun, Tian Yanan, Guo Lin, Lu Renquan
Primary Institution: Fudan University, Shanghai, China
Hypothesis
Calpain 2 is a key regulator of Lenvatinib resistance and cancer stem cell traits in hepatocellular carcinoma.
Conclusion
Calpain 2 promotes Lenvatinib resistance through both enzyme-dependent and independent mechanisms.
Supporting Evidence
- Calpain 2 expression was significantly higher in Lenvatinib-resistant HCC cell lines.
- Knocking down Calpain 2 sensitized HCC cells to Lenvatinib treatment.
- Overexpression of Calpain 2 conferred resistance to Lenvatinib in sensitive HCC cell lines.
- Calpain 2 was identified as a novel key member of the calpain family for mediating Lenvatinib resistance.
- Calpain 2 promoted cancer stem cell traits in HCC cells.
- Calpain 2's function involved both enzyme-dependent and independent mechanisms.
Takeaway
Calpain 2 helps liver cancer cells resist a drug called Lenvatinib, making it harder to treat the cancer.
Methodology
The study used bioinformatic analysis, in vitro and in vivo experiments to investigate the role of Calpain 2 in Lenvatinib resistance.
Potential Biases
Potential bias in patient enrollment and individual heterogeneity affecting treatment response.
Limitations
The study was retrospective with a small sample size and short follow-up time.
Participant Demographics
12 advanced hepatocellular carcinoma patients who received Lenvatinib treatment.
Statistical Information
P-Value
0.06
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website